1.A indication for small bowel resection.
Journal of the Korean Surgical Society 1991;40(1):61-67
No abstract available.
2.A clinical study of the salivary gland tumors.
Journal of the Korean Surgical Society 1991;40(6):697-702
No abstract available.
Salivary Glands*
3.A clinical study of peptic ulcer perforation.
Journal of the Korean Surgical Society 1993;45(6):946-955
No abstract available.
Peptic Ulcer Perforation*
;
Peptic Ulcer*
4.A clinical review of the neck mass.
Journal of the Korean Surgical Society 1991;40(4):415-424
No abstract available.
Neck*
6.The clinical analysis of choledochal cyst.
Seok Won CHIM ; Young Joo LEE ; Won Jin CHOI
Journal of the Korean Surgical Society 1993;45(4):527-535
No abstract available.
Choledochal Cyst*
8.Significance of preoperative abdominal computed tomography in gastric cancer patients.
Young Cheol LEE ; Won Jin CHOI ; Chul Soon CHOI
Journal of the Korean Surgical Society 1992;43(5):653-660
No abstract available.
Humans
;
Stomach Neoplasms*
9.Immunohistochemical Study on the Expression of Mutated p53 Protein and Bcl-2 Protein in Melanocytic Lesions of Skin.
Wha Jin LEE ; Joon Hyuk CHOI ; Won Hee CHOI
Korean Journal of Pathology 1997;31(2):112-120
To investigate the immunohistochemical expression of mutated p53 protein and bcl-2 protein in the cutaneous melanocytic lesion, 15 cases of compound nevus, 10 cases of congenital melanocytic nevus, 15 cases of primary malignant melanoma(4 cases less than 1.5 mm thick and 11 cases more than 1.5 mm thick), and 10 cases of metastatic malignant melanoma(7 cases in lymph node and 3 cases in soft tissue) were examined. All cases of compound nevi and of congenital melanocytic nevi showed no immunoreactivity for p53 protein. p53 protein overexpression was observed in 75%(3/4) wth primary malignant melanoma less than 1.5 mm thick, 81%(9/11) with primary malignant melanoma more than 1.5 mm thick, and 100%(10/10) with metastatic malignant melanoma. The difference in p53 protein overexpression was statistically significant between benign nevi and malignant melanoma(p<0.01). Bcl-2 protein expression was observed in 73%(11/15) with compound nevus, 70%(7/10) with congenital melanocytic nevus, 75% (3/4) in primary malignant melanoma less than 1.5 mm thick, 54%(6/11) with primary malignant melanoma more than 1.5 mm thick, and 40%(4/10) with metastatic malignant melanoma. These findings suggested that mutation of p53 gene may be an important mechanism in the development of malignant melanoma. Although bcl-2 protein was expressed in cutaneous melanocytic lesion, no correlation was found between p53 protein and bcl-2 protein expression in malignant melanoma.
Genes, p53
;
Lymph Nodes
;
Melanoma
;
Nevus
;
Nevus, Pigmented
;
Skin*
10.Immunohistochemical Study on the Expression of Mutated p53 Protein and Bcl-2 Protein in Melanocytic Lesions of Skin.
Wha Jin LEE ; Joon Hyuk CHOI ; Won Hee CHOI
Korean Journal of Pathology 1997;31(2):112-120
To investigate the immunohistochemical expression of mutated p53 protein and bcl-2 protein in the cutaneous melanocytic lesion, 15 cases of compound nevus, 10 cases of congenital melanocytic nevus, 15 cases of primary malignant melanoma(4 cases less than 1.5 mm thick and 11 cases more than 1.5 mm thick), and 10 cases of metastatic malignant melanoma(7 cases in lymph node and 3 cases in soft tissue) were examined. All cases of compound nevi and of congenital melanocytic nevi showed no immunoreactivity for p53 protein. p53 protein overexpression was observed in 75%(3/4) wth primary malignant melanoma less than 1.5 mm thick, 81%(9/11) with primary malignant melanoma more than 1.5 mm thick, and 100%(10/10) with metastatic malignant melanoma. The difference in p53 protein overexpression was statistically significant between benign nevi and malignant melanoma(p<0.01). Bcl-2 protein expression was observed in 73%(11/15) with compound nevus, 70%(7/10) with congenital melanocytic nevus, 75% (3/4) in primary malignant melanoma less than 1.5 mm thick, 54%(6/11) with primary malignant melanoma more than 1.5 mm thick, and 40%(4/10) with metastatic malignant melanoma. These findings suggested that mutation of p53 gene may be an important mechanism in the development of malignant melanoma. Although bcl-2 protein was expressed in cutaneous melanocytic lesion, no correlation was found between p53 protein and bcl-2 protein expression in malignant melanoma.
Genes, p53
;
Lymph Nodes
;
Melanoma
;
Nevus
;
Nevus, Pigmented
;
Skin*
Result Analysis
Print
Save
E-mail